SEC Company Response from Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747) (SCNI) — May 1, 2015
Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)
Date: May 1, 2015 · CIK: 0001611747 · Accession: 0001213900-15-003180
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-201283
Letter
AEGIS CAPITAL CORP.
Seventh Avenue
18th Floor
New York, NY 10019
May 1,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: BiondVax Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed April 30, 2015
File No. 333-201283
Ladies and Gentlemen:
The undersigned, as the representative of the underwriters, hereby joins in the request of BiondVax Pharmaceuticals Ltd. to cancel the representative’s acceleration request submitted to the Securities and Exchange Commission on April 28, 2015.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS
CAPITAL CORP.
810
Seventh Avenue
18th
Floor
New York,
NY 10019
May
1,
2015
VIA
EDGAR
United
States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
BiondVax Pharmaceuticals Ltd.
Registration
Statement on Form F-1
Filed
April 30, 2015
File
No. 333-201283
Ladies and
Gentlemen:
The undersigned, as the representative of the underwriters, hereby joins in the request of BiondVax Pharmaceuticals
Ltd. to cancel the representative’s acceleration request submitted to the Securities and Exchange Commission on April 28,
2015.
Very truly yours,
AEGIS CAPITAL CORP.
By: AEGIS CAPITAL CORP.
By:
/s/ Anthony Monaco
Name: Anthony M. Monaco
Title: Chief Compliance Officer